Glyconics, which is part of the Deepbridge Life Sciences EIS portfolio, has secured £1.5 million in an Enterprise Investment Scheme (EIS) funding round ahead of a series A round next year. 

The innovative diagnostics start-up, with offices in Cambridge, Norwich and Basingstoke, has raised well over the intended £850,000, which will now fund a large-scale trial programme of Glyconics’ game-changing point-of-care diabetes screening tool, Glyconics-SX™, prior to applying for regulatory approval and CE marketing. 

Dr Kam Pooni, CEO of Glyconics, commented:  

“Glyconics offers a transformational, cost-efficient, rapid and non-invasive approach to diabetes screening – and it is testament to this pioneering device and all at Team Glyconics that this raise was so significantly over-subscribed. We are delighted to be continuing with our existing investors and, of course, welcome our new investors from Wealth Club and other private investors to the fold.” 

Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).